Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Prosperi, Mattia C F ^a,b   Fabbiani, Massimiliano ^a   Fanti, Iuri ^a   Zaccarelli, Mauro ^c   Colafigli, Manuela ^a   Mondi, Annalisa ^a   D'Avino, Alessandro ^a   Borghetti, Alberto ^a   Cauda, Roberto ^a   Di Giambenedetto, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

HAART; HIV; Side effects; Therapy na ve; Toxicity

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LANINAMIVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAMPIDINE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZALTACIBINE; ZIDOVUDINE;

ADVERSE DRUG REACTION; AGE; ARTICLE; BISEXUALITY; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID METABOLISM; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENDER; GENOTYPE; HEMATOLOGIC DISEASE; HETEROSEXUALITY; HIGH RISK PATIENT; HOMOSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PATIENT INFORMATION; PREDICTION; PROBABILITY; RETROSPECTIVE STUDY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; PREGNANCY; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84868642013     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-296     Document Type: Article

References (44)

1. Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, . HIV Outpatient Study Investigators Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27-34. 10.1097/01.qai.0000233310.90484.16, 16878047, HIV Outpatient Study Investigators.
2. Vo TT, Ledergerber B, Keiser O, Hirschel B, Furrer H, Battegay M, Cavassini M, Bernasconi E, Vernazza P, Weber R, . Swiss HIV Cohort Study Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008, 197:1685-1694. 10.1086/588141, 18513155, Swiss HIV Cohort Study.
3. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M, . Swiss HIV Cohort Study Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010, 170:57-65. 10.1001/archinternmed.2009.432, 20065200, Swiss HIV Cohort Study.
4. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008, 22:F17-F24. 2644883, 18753925, Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups.
5. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011, 76:1403-1409. 10.1212/WNL.0b013e31821670fb, 21502598.
6. Fabbiani M, Bracciale L, Doino M, D'Avino A, Marzocchetti A, Navarra P, Cauda R, De Luca A, Di Giambenedetto S. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. J Infect 2011, 62:319-321. 10.1016/j.jinf.2011.02.004, 21329725.
7. Islam F, Wu J, Jansson J, Wilson D. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012, in press.
8. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407-414. 10.1097/00126334-200312010-00008, 14615659.
9. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD, . EuroSIDA Study Group Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21:743-752. 10.1089/aid.2005.21.743, 16218797, EuroSIDA Study Group.
10. Yuan Y, L'italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006, 7:156-162. 10.1111/j.1468-1293.2006.00355.x, 16494629.
11. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000, 14:499-507. 10.1097/00002030-200003310-00005, 10780712.
12. Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A, . Swiss HIV Cohort Study Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011, 203:246-257. 10.1093/infdis/jiq043, 3071070, 21288825, Swiss HIV Cohort Study.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
14. Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events. Publish date: December, 2004. Available at: http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf (13 March 2012, date last accessed), Division of AIDS (DAIDS).
15. Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, Bella D, Pastore G, Ladisa N, Minoli L, Sotgiu G, Mazzotta F, Lo Caputo S, Di Perri G, Filice G, Tinelli C, Carosi G, . EPOKA-MASTER Study Group Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis 2005, 5:58. 10.1186/1471-2334-5-58, 1188059, 16018804, EPOKA-MASTER Study Group.
16. Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A, . EuroSIDA study group A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med 2011, 12(5):259-68. 10.1111/j.1468-1293.2010.00877.x, 20812948, EuroSIDA study group.
17. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2011, 1-167. Department of Health and Human Services, Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (13 March 2012, date last accessed), Panel on Antiretroviral Guidelines for Adults and Adolescents.
18. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev 2010, 12:67-75.
19. Scourfield A, Zheng J, Chinthapalli S, Waters L, Martin T, Mandalia S, Nelson M. Discontinuation of Atripla® as first-line therapy in HIV-1 infected individuals. AIDS 2012, in press.
20. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, Bai F, Orofino G, Sighinolfi L, Gori A, Suter F, Maggiolo F. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010, 4:115-125. 2875721, 20517472.
21. Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection. Pharmacol Res 2008, 58:173-182. 10.1016/j.phrs.2008.07.007, 18708144.
22. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 2007, 4:106-119. 10.1016/S1550-8579(07)80025-8, 17707845.
23. Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, Allison JJ, Willig JH, Raper JL, Wilcox CM, Saag MS. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008, 24:1347-1355. 10.1089/aid.2008.0083, 2928492, 19032064.
24. Aulicino PC, Bello G, Rocco C, Romero H, Mangano A, Morgado MG, Sen L. Description of the first full-length HIV type 1 subtype F1 strain in Argentina: implications for the origin and dispersion of this subtype in South America. AIDS Res Hum Retroviruses 2007, 23:1176-1182. 10.1089/aid.2007.0038, 17961101.
25. Teixeira SLM, Guimaraes ML, Leite T, Coelho A, Campos DP, Veloso V, Morgado MG. Disease progression in a cohort of HIV-1 positive patients from Rio de Janeiro, Brazil: potential role of HIV-1 subtypes and HLA-B alleles 2011, Rome: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Abstract n CDA105.
26. Taylor B, Sobieszczyk M, McCutchan F, Hammer S. The challenge of HIV-1 subtype diversity. N Engl J Med 2008, 358:1590-1602. 10.1056/NEJMra0706737, 2614444, 18403767.
27. Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS 2007, 21:1579-1589. 10.1097/QAD.0b013e3281532b31, 3460378, 17630553.
28. Rekić D, Clewe O, Röshammar D, Flamholc L, Sönnerborg A, Ormaasen V, Gisslén M, Abelö A, Ashton M. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy. AAPS J 2011, 13:598-605. 10.1208/s12248-011-9299-0, 3231858, 21913053.
29. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN. Changes over time in risk of initial virologic failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006, 166:521-528. 10.1001/archinte.166.5.521, 16534038.
30. Lampe FC, Smith CJ, Madge S, Kinloch-de Loes S, Tyrer M, Sabin CA, Chaloner C, Youle M, Johnson MA, Phillips AN. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007, 167:692-700. 10.1001/archinte.167.7.692, 17420428.
31. Prosperi MC, Cozzi-Lepri A, Antinori A, Cassola G, Torti C, Ursitti MA, Pellizzer GP, Giacometti A, d'Arminio Monforte A, De Luca A, . Icona Foundation Study Group Favourable evolution of virologic and immunological profiles in treated and untreated patients in Italy in the period 1998-2008. HIV Med 2011, 12:174-182. 10.1111/j.1468-1293.2010.00866.x, 20726904, Icona Foundation Study Group.
32. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009, 49:1582-1590. 10.1086/644768, 2871149, 19845473.
33. Di Giambenedetto S, Prosperi M, Fanti I, Bruzzone B, Paolucci S, Penco G, Meini G, Di Biagio A, Paolini E, Micheli V, Meraviglia P, Castelli P, Corsi P, Gonnelli A, Fabbiani M, Zazzi M, De Luca A, . ARCA Collaborative Group Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. Clin Microbiol Infect 2011, 17:1352-1355. ARCA Collaborative Group.
34. Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A, . EuroSIDA group Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011, 66:901-911. 10.1093/jac/dkr006, 21393179, EuroSIDA group.
35. Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A, . SEHERE consortium Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother 2011, 66:1886-1896. 10.1093/jac/dkr171, 21624929, SEHERE consortium.
36. Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, Maserati R, Gianotti N, Penco G, Setti M, Di Giambenedetto S, Butini L, Vivarelli A, Trezzi M, De Luca A. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 2009, 64:607-615. 10.1093/jac/dkp246, 19608581.
37. Di Giambenedetto S, Bracciale L, Colafigli M, Cattani P, Pinnetti C, Bacarelli A, Prosperi M, Fadda G, Cauda R, De Luca A. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther 2007, 12:835-839.
38. Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A, . Antiretroviral Resistance Cohort Analysis Study Group Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antivir Ther 2009, 14:359-369. Antiretroviral Resistance Cohort Analysis Study Group.
39. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M, . Antiretroviral Therapy (ART) Cohort Collaboration HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006, 368:451-458. Antiretroviral Therapy (ART) Cohort Collaboration.
40. Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A, . ICoNA Foundation Study Group Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med 2010, 11:104-113. 10.1111/j.1468-1293.2009.00750.x, 19732176, ICoNA Foundation Study Group.
41. Prosperi MC, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, Bazso F, Sönnerborg A, Schülter E, Struck D, Ulivi G, Vandamme AM, Vercauteren J, Zazzi M, . EuResist and Virolab study groups Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther 2009, 14:433-442. EuResist and Virolab study groups.
42. Prosperi MC, Di Giambenedetto S, Fanti I, Meini G, Bruzzone B, Callegaro A, Penco G, Bagnarelli P, Micheli V, Paolini E, Di Biagio A, Ghisetti V, Di Pietro M, Zazzi M, De Luca A, . ARCA cohort A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. BMC Med Inform Decis Mak 2011, 11:40. 10.1186/1472-6947-11-40, 3144446, 21672248, ARCA cohort.
43. Larder BA, Revell A, Mican JM, Agan BK, Harris M, Torti C, Izzo I, Metcalf JA, Rivera-Goba M, Marconi VC, Wang D, Coe D, Gazzard B, Montaner J, Lane HC. Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience. AIDS Patient Care STDS 2011, 25:29-36. 10.1089/apc.2010.0254, 3030912, 21214377.
44. Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB, Freedberg KA. Predicting virologic failure in an HIV clinic. Clin Infect Dis 2010, 50:779-786. 3101804, 20121574.